Patents Assigned to Cobra Therapeutics Limited
-
Patent number: 6503738Abstract: A scalable method for the production of highly purified plasmid DNA in Escherichia coli is described, which method includes growing plasmid-containing cells to a high biomass in exponential growth and lysing the cells by raising the pH of the culture to a carefully controlled pH value in which chromosomal DNA is denatured but plasmid DNA is reversibly renatured. The method has been developed for the production of pharmaceutical grade DNA for use in in vivo and ex vivo gene therapy.Type: GrantFiled: June 10, 1999Date of Patent: January 7, 2003Assignee: Cobra Therapeutics LimitedInventors: David R. Thatcher, Anthony Hitchcock, Julian A. J. Hanak, Diane L. Varley
-
Patent number: 6479464Abstract: The invention encompasses a transfection complex comprising a polypeptide comprising the contiguous 29 amino acids: 6G's, 2F's, 2L's, 1W, 4R's, 2E's, 2N's, 3K's, 1T, 1S, 1A, 1Y, 1M, 1C, and 1I, and having additional cationic residues to provide a net number of positive charges of equal to or greater than 8, and an isolated nucleic acid, and methods of transfecting cells using this transfection complex. The invention also includes a polypeptide having an amino acid composition including these 29 amino acids, as well as mixtures of polypeptides in which this polypeptide is present.Type: GrantFiled: February 12, 1998Date of Patent: November 12, 2002Assignee: Cobra Therapeutics LimitedInventors: Adrian Mark Haines, Ross Owen Phillips, John Hamilton Welsh, David Robert Thatcher, Alistair Simpson Irvine, Roger Kingdon Craig
-
Publication number: 20020165173Abstract: Disclosed are DNA elements and constructs useful for obtaining tumour-selective gene expression in tumours having a mutated &bgr;-catenin/APC pathway. In particular, the use of these constructs to express genes encoding therapeutic proteins in colorectal cancer cells is described. The constructs comprise multiple repeats of a TCF-binding element operably linked to a promoter. By means of such a construct, tumour cell-specific expression of a prodrug-converting enzyme such as nitroreductase may be achieved. Coupled with systemic administration of a suitable prodrug, such as CB1954, selective killing of such tumour cells can be demonstrated.Type: ApplicationFiled: March 2, 2001Publication date: November 7, 2002Applicant: Cobra Therapeutics LimitedInventors: Lawrence S. Young, Kai S. Lipinski, Christopher J. Wrighton
-
Publication number: 20020123037Abstract: The invention relates to a process for the selection from a gene library of a gene encoding an enzyme that is capable of catalyzing the conversion of a prodrug to its active drug form. The method comprises contacting a library of lysogenic bacteria with a prodrug that causes activation of bacterial RecA when converted to its active drug form. Activation of RecA causes lysis of the bacteria, so allowing separation of bacteriophage particles released into the medium, and their subsequent genotypic analysis to isolate nucleic acid molecules in the library that encode a desired prodrug-activating enzyme.Type: ApplicationFiled: November 6, 2001Publication date: September 5, 2002Applicant: Cobra Therapeutics LimitedInventor: Peter F Searle
-
Publication number: 20020106789Abstract: The present invention relates to a polynucleotide comprising a ubiquitous chromatin opening element (UCOE) which is not derived from13.The polynucleotide of any one of claims 1 to 7, wherein the UCOE comprises the sequence of Figure 20 between nucleotides 1 to 7627 or a functional homologue or fragment thereof. an LCR. The present invention also relates to a vector comprising the polynucleotide sequence, a host cell comprising the vector, use of the polynucleotide, vector or host cell in therapy and in an assay, and a method of identifying UCOEs. The UCOE opens chromatin or maintains chromatin in an open state and facilitates reproducible expression of an operably-linked gene in cells of at least two different tissue types.Type: ApplicationFiled: July 21, 1999Publication date: August 8, 2002Applicant: Cobra therapeutics LimitedInventors: Michael Antoniou , Robert Crombie
-
Patent number: 6395516Abstract: The invention relates to a vessel for mixing a cell lysate. The invention also relates to a method of using the vessel to mix a cell lysate in order to obtain high-purity products such as nucleic acids or proteins for use in a variety of applications. The invention also relates to a method for monitoring the degree of cell lysis in a cell suspension by measuring the viscosity of the cell suspension.Type: GrantFiled: March 10, 2000Date of Patent: May 28, 2002Assignee: Cobra Therapeutics LimitedInventors: Alvin William Nienow, Antony Gordon Hitchock, Grainne Lois Riley
-
Patent number: 6258840Abstract: Novel carbamate ester analogues or derivatives of Quercetin (prodrugs) are provided which have enhanced aqueous solubility and which are especially suitable for use as biodegradable prodrugs in pharmaceutical compositions formulated for clinical use.Type: GrantFiled: July 20, 1999Date of Patent: July 10, 2001Assignee: Cobra Therapeutics LimitedInventors: Bernard Thomas Golding, Roger John Griffin, Charmaine Paulina Quarterman, John Alfred Slack, Jonathan Gareth Williams
-
Patent number: 6218112Abstract: Methods of screening for peptides useful in a gene delivery system to provide optimal transfection of cells based on kinetic parameters of the peptide-nucleic acid bimolecular interaction are described.Type: GrantFiled: December 22, 1997Date of Patent: April 17, 2001Assignee: Cobra Therapeutics LimitedInventors: David R. Thatcher, Paula E. Wilks
-
Patent number: 5981735Abstract: A scalable method for the production of highly purified plasmid DNA in Escherichia coli is described, which method includes growing plasmid-containing cells to a high biomass in exponential growth and lysing the cells by raising the pH of the culture to a carefully controlled pH value in which chromosomal DNA is denatured but plasmid DNA is reversibly renatured. The method has been developed for the production of pharmaceutical grade DNA for use in in vivo and ex vivo gene therapy.Type: GrantFiled: February 12, 1997Date of Patent: November 9, 1999Assignee: Cobra Therapeutics LimitedInventors: David R. Thatcher, Anthony Hitchcock, Julian A.J. Hanak, Diane L. Varley
-
Patent number: 5972708Abstract: A system is described which utilizes a novel system of repressor titration for maintenance of a plasmid useful in gene therapy and production of a recombinant protein. The system utilizes a transformed host cell containing a plasmid including an operator susceptible to binding by a repressor expressed in trans, a first chromosomal gene encoding the repressor, and a second chromosomal gene that is functionally associated with an operator and essential for cell growth, wherein the plasmid is present in the cell in sufficient numbers to titrate the repressor such that the essential gene is expressed, thereby permitting cell growth.Type: GrantFiled: October 21, 1998Date of Patent: October 26, 1999Assignee: Cobra Therapeutics LimitedInventors: David J. Sherratt, Steven G. Williams, Julian A.J. Hanak